Capstone Investment Advisors
JAZZ icon

Capstone Investment Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Capstone Investment Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-51,000
Closed -$6.14M – 2275
2024
Q1 		$6.14M Hold
51,000
– – 0.02% 381
2023
Q4 		$6.27M Buy
+51,000
New +$6.36M 0.02% 456

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capstone Investment Advisors's JAZZ Position: Q4 2024 in Review

Capstone Investment Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2024, closing a stake of 2,932 shares — an estimated $327K sold.

Capstone Investment Advisors first reported a position in JAZZ in Q1 2016 and held it in 5 quarters. The position peaked at $856K in Q4 2023. 508 funds tracked by Wall St. Rank hold JAZZ as of Q4 2024.

  • Capstone Investment Advisors reported no remaining Jazz Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capstone Investment Advisors sold 2,932 Jazz Pharmaceuticals shares in Q4 2024, an estimated $327K.
  • Capstone Investment Advisors first reported a position in Jazz Pharmaceuticals in Q1 2016 and held it in 5 quarters.
  • Capstone Investment Advisors's Jazz Pharmaceuticals position peaked at $856K in Q4 2023.
  • 508 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2024.

Based on Capstone Investment Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.